UK pricing pressure
The UK market continues to face significant pricing erosion and pressure. Management acknowledged this is an ongoing challenge but expects new product approvals to provide bottom-line support over time.
MARKSANS / Q2-FY26 / risks
Keep the risk register visible.
Marksans Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
UK new product impact delayed
While 3 MHRA approvals were received, management indicated that meaningful revenue impact from UK high-value product launches will only start in Q3 2026, suggesting continued margin pressure in near term.
US tariff uncertainty resolution
Although management expressed confidence that pharma tariffs are off the table, this was described as emerging clarity in the last 1-1.5 months. The reversibility risk remains given political dynamics.
Working capital normalization timeline
The company holds 5-6 months of inventory (vs typical 2-3 months) and management expects normalization only from Q1 FY27, tying up significant capital for multiple quarters.